



Food and Drug Administration
OFFICE OF CRIMINAL INVESTIGATIONS
MEMORANDUM OF INTERVIEW

CASE NUMBER: 2005-MWM-715-0153-J
CASE TITLE: ALBERT POET
DOCUMENT NUMBER: 99921
PERSON INTERVIEWED: Theresa [REDACTED]
PLACE OF INTERVIEW: Camden County, New Jersey
DATE OF INTERVIEW: 08/15/2006
TIME OF INTERVIEW: 12:15 p.m.
INTERVIEWED BY: Marc Hess, Special Agent

OTHER PERSONS PRESENT: None

Theresa [REDACTED] was telephonically contacted and advised of the identity of the interviewing agent and the nature of the interview. E [REDACTED] then provided the following information:

B [REDACTED] resides at [REDACTED] Manahawkin, New Jersey (NJ), 08050, 609/[REDACTED] and, 609/[REDACTED]

B [REDACTED] has been a patient of the medical practice of Dr. Albert Poet at Manahawkin, NJ, for at least ten years. She initially was treated by Poet for skin cancer spots. In or about 2004, E [REDACTED] consulted with Poet concerning treatment for skin wrinkles. Poet recommended treatment with a drug that he referred to as both Botox and Botulinum Toxin. Poet indicated that Botox was the "trade" or manufacturers name of the drug while Botulinum Toxin was the "medical" name. This discussion did not communicate to B [REDACTED] that these were the same drug. Poet further advised E [REDACTED] that a separate Botulinum Toxin drug was being utilized in Europe and was awaiting FDA approval. Poet indicted that he utilized a product similar to Botox which was cheaper and more effective. Poet may have indicated that this drug was manufactured in Canada. B [REDACTED] main concern in these discussion was to hear that the drug she would be treated with "works well". Poet indicated that the drug with which he would treat E [REDACTED] was safe and effective since he used it on himself. Poet further indicated that he had treated other patients with this drug and they were pleased with their treatments.

E [REDACTED] did not receive any Botulinum Toxin (BT) type treatment from any other doctor.

B [REDACTED] began her BT treatments with Poet in or about 2004 and received eight treatments.

Poet administered the treatments at his practice in Manahawkin, NJ. A female office assistant, Laurie (last name unknown) was present for the treatments and held Buternick's hand due to the discomfort of the treatment.

Poet charged B [REDACTED] by the vial for the treatments. The price was initially \$400.00 per vial and rose over time.

B [REDACTED] believed that she signed a one-page consent form.

B [redacted] did not notice any adverse side effects from the Botox treatments.

B [redacted] did not believe that she was receiving the trademark drug named Botox because Poet had indicated otherwise in their discussions.

B [redacted] was advised by Poet that she was being treated with a Botulinum Toxin based drug which was similar to the trademark Botox product but which was not that product. B [redacted] concurred in these treatments based on Poet's description of this drug to her. B [redacted] trusted Poet and expected that he would have researched the appropriate medical literature to determine that the drug which he was using to treat her was safe and effective.

The price of BT treatments with Poet rose from \$400.00 to \$700.00 during Buternick's time as a patient with Poet. During this period Poet also advised B [redacted] that he had switched to a form of Botulinum Toxin known as Androgen. B [redacted] did not know the reason for the switch and did not recall any further explanation by Poet of the matter.

Poet recently telephonically contacted B [redacted] and advised her that he had treated her with a BT drug which was not FDA approved. He advised that she should tell the truth if the FDA contacted her to investigate this matter.

NAME-TITLE _____ NAME-TITLE _____

Marc Hess, Special Agent

DATE 08/30/2006

DATE

APPROVED: _____

Kim A. Rice, Special Agent in Charge

DATE: 09/11/2006

DISTRIBUTION: ORIG: MWM
CC: AD-IOD
CC: MIF - SA KORB
CC: PHP

ATTACHMENTS: n/a